loader2
Partner With Us NRI

Divis Laboratories Ltd share Price Today

Company details

3,895.60
3,954.70
3,051.00
4,100.00
6M Return 10.57%
1Y Return 19.36%
Mkt Cap.(Cr) 103,818.29
Volume 267,526
Div Yield 0.77%
OI
-
OI Chg %
-
Volume 267,526

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Margins tumble to historical low; outlook cautious…
About The Stock

    Divi’s is engaged in manufacturing generic APIs and intermediates, custom synthesis (CS) of active ingredients and advanced intermediates for pharma MNCs, other speciality chemicals like Carotenoids and complex compounds like peptides and Nucleotide revenues.

    • In CS, the company maintains a strong relationship with global big pharma players while in generics it enjoys significant market share in products like Naproxen, Dextromethorphan and Gabapentin among others
    • Divi’s is fully backward integrated in products with high market share. The management intends to follow suit in other products
Q3FY23 Results

    Dismal set of numbers miss our expectations.

    • Revenues de-grew 31.5% YoY to ₹ 1708 crore
    • EBITDA margins declined 2010 bps YoY to 23.9% due to 1) high-cost inventory 2) acute pricing pressure in generics 3) replacement of old safety systems with new ones and other maintenance
    • Adjusted PAT declined 66.0% YoY to ₹ 307 crore

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Divi's Laboratories announced Q3FY24 & 9MFY24 results:

Consolidated Q3FY24:

  • Total Income: Rs 1,950 crore, compared to Rs 1,821 crore in the corresponding quarter of the previous year.
  • Material Consumption: Approximately 39% of sales revenue.
  • Profit Before Tax (PBT): Rs 489 crore, compared to Rs 435 crore in the corresponding quarter of the previous year.
  • Profit After Tax (PAT): Rs 358 crore, compared to Rs 306 crore in the corresponding quarter of the previous year.

Standalone Q3FY24:

  • Total Income: Recorded at Rs 1,902 crore in Q3FY24 compared to Rs 1,807 crore in Q3FY23.
  • Profit Before Tax (PBT): Stood at Rs 490 crore in Q3FY24, up from Rs 439 crore in Q3FY23.
  • Profit After Tax (PAT): Amounted to Rs 358 crore in Q3FY24, higher than the Rs 310 crore in Q3FY23.
  • Forex Gain: Registered at Rs 17 crore in Q3FY24, decreased from Rs 49 crore in Q3FY23.

Consolidated 9MFY24:

  • Total Income: Rs 5,804 crore, compared to Rs 6,099 crore in the corresponding previous period.
  • Profit After Tax (PAT): Rs 1,062 crore, compared to Rs 1,502 crore in the corresponding previous period.
  • Forex Gain: Rs 32 crore, compared to Rs 134 crore in the previous 9-month period.

Standalone 9MFY24:

  • Total Income: For 9MFY24, it amounted to Rs 5,665 crore, down from Rs 6,003 crore in 9MFY23.
  • Profit Before Tax (PBT): For 9MFY24, it was Rs 1,432 crore, a decrease from Rs 1,886 crore in 9MFY23.
  • Profit After Tax (PAT): For 9MFY24, it reached Rs 1,045 crore, down from Rs 1,489 crore in 9MFY23.
  • Forex Gain: For 9MFY24, it stood at Rs 29 crore, a decline from Rs 137 crore in 9MFY23.

Result PDF

View Other Company Results

Divis Laboratories Ltd shares SWOT Analysis

Strengths (7)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Company with No Debt

Weakness (3)

  • Degrowth in Revenue and Profit
  • Declining Net Cash Flow : Companies not able to generate net cash
  • Major fall in TTM Net Profit

Opportunity (2)

  • Results Screener: Stocks with upcoming results which are seeing positive shifts in share price
  • RSI indicating price strength

Threats (2)

  • High PE (PE > 40)
  • Increasing Trend in Non-Core Income

Resistance and support

R1 3,945.1
R2 3,979.5
R3 4,004.2
Pivot

3,920.35

S1 3,886.0
S2 3,861.3
S3 3,826.9
EMA SMA
3,864.4
3,775.2
3,722.8
3,669.1
3,884.3
3,702.5
3,722.5
3,692.2
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
NORTHERN LIGHTS FUND TRUST III RONDURE NEW WORLD FUND Block Purchase 2023-10-20 3637.7 43478 BSE
RONDURE NEW WORLD FUND Block Sell 2023-10-20 3637.7 43478 BSE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-11-14 3271.4 209124 NSE
Name Category Shares
NILIMA PRASAD DIVI PROMOTER 20.34%
SATCHANDRA KIRAN DIVI PROMOTER 20.34%
SWARNA LATHA DIVI PROMOTER 5.27%
MURALI KRISHNA PRASAD DIVI PROMOTER 2.85%
DIVI'S BIOTECH PRIVATE LIMITED PROMOTER 3.01%

OUR RESEARCH VIEW

Investment recommendation
Margins tumble to historical low; outlook cautious…
Call Date
03 Feb 2023
Entry Price 2,860.00
Target Price 2,945.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Divis Laboratories Ltd Stocks COMPARISON

Financials( in Cr) Divis Laboratories Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Zydus Lifesciences Ltd Dr Reddys Laboratories Ltd
Price 3,910.75 1,531.40 1,399.05 1,051.40 5,799.55
% Change 0.47 0.26 -0.54 5.45 -1.28
Mcap Cr 103,818.29 367,434.16 112,954.68 105,795.44 96,746.93
Revenue TTM Cr 7,767.51 43,885.68 15,790.60 17,237.40 24,669.70
Net Profit TTM Cr 1,823.38 8,560.84 2,513.47 1,997.30 4,507.30
PE TTM 75.08 39.17 26.53 27.46 17.34
1 Year Return 19.36 60.69 51.61 103.07 28.35
ROCE 19.30 16.79 14.76 16.25 25.99
ROE 14.89 16.46 10.66 14.05 21.21
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 12,767.09 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 45,581.63 -35,822.31
LAST 3M 105,886.10 -42,131.07
LAST 6M 173,680.57 48,055.67
LAST 12M 265,486.86 128,722.00
Divi`s Laboratories Limited - Board Meeting

May 15, 2024 l NSE Announcement

Divis Laboratories declare Quarterly Result

May 15, 2024 l BSE Announcement

Date Action Type Ratio
Aug 11, 2023 Dividend 1500
Aug 11, 2022 Dividend 1500

Divis Laboratories Ltd Information

Stock PE (TTM)
75.08
Promoter Holding
51.92%
Book Value
477.5365
ROCE
19.3%
ROE
14.89%
Registered Address

1-72-23(P)/DIVIS/303 Divi Towe, Cyber Hills Gachibowli, Hyderabad, Telangana, 500032

Tel : 91-40-23786300/23786352/400
Email : mail:divislaboratories.com; cs:divislaboratories.c
Website : http://www.divislabs.com
Registrar

Karvy Computershare Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 532488
NSE Code : DIVISLAB
Book Closure Date (Month) :
BSE Group : A
ISIN : INE361B01024

FAQ’s on Divis Laboratories Ltd Shares

You can buy Divis Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Divis Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 17, 2024 03:59 PM the closing price of Divis Laboratories Ltd was Rs.3,910.75.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 17, 2024 03:59 PM, the market cap of Divis Laboratories Ltd stood at Rs. 103,818.29.

The latest PE ratio of Divis Laboratories Ltd as of May 17, 2024 03:59 PM is 75.08

The latest PB ratio of Divis Laboratories Ltd as of May 17, 2024 03:59 PM is 0.12

The 52-week high of Divis Laboratories Ltd share price is Rs. 4,100.00 while the 52-week low is Rs. 3,051.00

According to analyst recommendations, Divis Laboratories Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app